The regulatory path forward for CBD

While not everyone was on the same page about the legal path forward for hemp-derived CBD during Friday’s marathon FDA hearing, multiple speakers made clear that the current situation is untenable, with one predicting a wave of lawsuits, and others demanding that the agency either crack down on companies marketing such products, or explicitly spell out that existing regulatory frameworks can accommodate them.